Biotech CEO Launches Paradigm-Shifting Drug Development Model


Dr. Charles Theuer’s “Unnecessary Expense” is published with ForbesBooks

This press release is issued on behalf of ForbesBooks (operated by Advantage Media Group under license).

NEW YORK (September 21, 2021) – Wasteful spending: an antidote to the billion dollar drug problem by the President and CEO of TRACON Pharmaceuticals, Dr. Charles Theuer, is now available. The book is published with ForbesBooks, the exclusive publisher of business books of Forbes, and is available on Amazon today.

The problem of skyrocketing drug prices in America is well documented. Driven by unchecked drug development spending, the average cost of $ 2 billion is being offloaded to patients and third-party payers at premium rates, perpetuating the accessibility challenges many healthcare consumers face today. hui.

With Unnecessary expenseDr. Theuer exposes the error at the heart of the billion dollar drug problem – that drug development costs cannot be controlled, arguing that the costs of clinical trials are not the price to be paid. pay to do business and instead can be limited by implementing an efficient and cost-effective approach to developing life-saving treatments. Theuer’s alternative approach to the outsourcing behaviors of large pharmaceutical companies is TRACON’s streamlined, aligned drug development model, which harnesses global innovation to benefit patients and enables drug innovators to stay motivated and engaged while ‘They navigate clinical trials and FDA approvals.

“A more streamlined approach to drug development will not only allow new therapies to reach the underserved populations who need them most in less time, but it will also create greater value for stakeholders,” Theuer explained. . “Patients will benefit, drug developers will receive fair profits to reward their continued commitment to innovation, and insurance companies will avoid paying higher prices for drugs approved for rare disease patients.” . “

Dr. Theuer’s work shows that there is a better way. With this new model, it becomes possible for a conscientious and equitably managed biotech company to be both economically and ethically successful in the drug development process, transform an industry, and ultimately save money. lives that would otherwise have been left on the margins of an inefficient system.

About Dr Charles Theuer

Since 2006, Dr Charles Theuer has been CEO, President and Director of TRACON Pharmaceuticals. Prior to assuming the leadership of TRACON, Dr Theuer was instrumental in bringing successful new oncology drugs to market, including Sutent® to treat advanced kidney cancer, while working as director of the clinical oncology at Pfizer. Dr Theuer previously held senior positions at renowned biotechnology companies including TargeGen, Inc. and IDEC Pharmaceutical Corp. Earlier in his career, Dr Theuer also worked at the National Cancer Institute and held academic positions at the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was certified in general surgery in 1997. Dr. Theuer’s previous research focused on the development of immunotoxins and cancer vaccines, translational work in cancer patients and the epidemiology of gastrointestinal cancer. He is married with two grown children and enjoys hiking, basketball training and sculling.

About ForbesBooks

Launched in 2016 in partnership with Advantage Media Group, ForbesBooks is Forbes’ exclusive publisher of business books. ForbesBooks offers businesses and thought leaders an innovative, fast, and premium publishing model, along with a suite of services designed to strategically and tactically support authors and promote their expertise. For more information, visit

Media contact

Courtney Morrill, ForbesBooks, [email protected]

Source link

Leave A Reply

Your email address will not be published.